Domača stran532523 • BOM
add
Biocon Ltd
Prejšnji trg. dan.
359,20 ₹
Dnevni razpon
358,30 ₹ - 366,50 ₹
Letni razpon
231,35 ₹ - 395,65 ₹
Tržna kapitalizacija
410,19 mrd. INR
Povprečni obseg
180,71 tis.
Razm. P/E
30,34
Dividendna donosnost
0,14 %
Primarna borza
NSE
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (INR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 35,90 mrd. | 3,70 % |
Stroški poslovanja | 21,42 mrd. | 8,03 % |
Čisti dohodek | −160,00 mio. | −112,74 % |
Čista dobičkovnost prihodkov | −0,45 | −112,40 % |
Earnings per share | −0,19 | −115,53 % |
EBITDA | 6,78 mrd. | −6,58 % |
Efektivna davčna stopnja | 72,46 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (INR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 26,50 mrd. | −30,00 % |
Skupna sredstva | 571,28 mrd. | 4,67 % |
Skupne obveznosti | 304,08 mrd. | 0,36 % |
Celoten lastniški kapital | 267,20 mrd. | — |
Shares outstanding | 1,23 mrd. | — |
Razmerje P/B | 2,11 | — |
Donosnost sredstev | — | — |
Donosnost kapitala | 1,56 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (INR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −160,00 mio. | −112,74 % |
Denar iz dejavnosti | — | — |
Denar iz naložb | — | — |
Denar iz financiranja | — | — |
Neto sprememba denarnih sredstev | — | — |
Prost denarni tok | — | — |
Vizitka
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Generalni direktor
Datum ustanovitve
1978
Sedež organizacije
Spletno mesto
Zaposleni
16.315
